Hillmen, P., Pettitt, A., Schuh, A., Milligan, D., Bowles, K., Bareford, D., . . . McKeown, A. (2014). Ofatumumab plus chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukaemia (CLL): Results of the phase III study COMPLEMENT 1 (OMB110911; NCRN-adopted).
Chicago-viite (17. p.)Hillmen, P., et al. Ofatumumab Plus Chlorambucil Versus Chlorambucil Alone in Patients with Untreated Chronic Lymphocytic Leukaemia (CLL): Results of the Phase III Study COMPLEMENT 1 (OMB110911; NCRN-adopted). 2014.
MLA-viite (9. p.)Hillmen, P., et al. Ofatumumab Plus Chlorambucil Versus Chlorambucil Alone in Patients with Untreated Chronic Lymphocytic Leukaemia (CLL): Results of the Phase III Study COMPLEMENT 1 (OMB110911; NCRN-adopted). 2014.